Collegium Pharmaceutical Stock News

STOUGHTON, Mass., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified specialty pharmaceutical company committed to improving the lives of people l

Today, we revisit Collegium Pharmaceutical, Inc., which has seen a 30% increase in its stock price since our last look at it in June 2022. Collegium Pharmaceutical has done a good job integrating Belb

STOUGHTON, Mass., Oct. 24, 2023 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified specialty pharmaceutical company committed to improving the lives of people l

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest

Collegium Pharmaceutical is a specialty pharmaceutical company focused on developing innovative treatments for chronic pain with abuse-deterrent technology. The company's financials show solid sales m

Collegium Pharmaceutical presents attractive value for investors with a forward earnings multiple of 4.5x and a 30% return on capital deployed. Q2 earnings indicate potential for momentum and a target

Although the revenue and EPS for Collegium Pharmaceutical (COLL) give a sense of how its business performed in the quarter ended June 2023, it might be worth considering how some key metrics compare w

STOUGHTON, Mass., July 20, 2023 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified specialty pharmaceutical company committed to improving the lives of people l

Collegium Pharmaceutical, Inc. (NASDAQ:COLL ) Q1 2023 Earnings Conference Call May 4, 2023 4:30 PM ET Company Participants Christopher James - Vice President, Investor Relations Joe Ciaffoni - Chief E

STOUGHTON, Mass., April 20, 2023 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified specialty pharmaceutical company committed to improving the lives of people

COLL vs. ZTS: Which Stock Is the Better Value Option?

Collegium Pharmaceutical, Inc. (NASDAQ:COLL ) Q4 2022 Earnings Conference Call February 23, 2023 4:30 PM ET Company Participants Christopher James - Vice President of Investor Relations at Collegium P

Collegium Pharmaceutical (COLL) delivered earnings and revenue surprises of 5.83% and 2%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

COLL vs. ZTS: Which Stock Is the Better Value Option?

Let's explore a Zacks screen that helps investors find 'Strong Buy' stocks trading near their highs as we head into February